Show simple item record Rubio Pérez, Carlota Tamborero Noguera, David Schroeder, Michael Philipp, 1986- Antolín Hernández, Albert, 1984- Déu Pons, Jordi Pérez Llamas, Christian, 1976- Mestres i López, Jordi González-Pérez, Abel López Bigas, Núria 2017-02-03T12:08:31Z 2017-02-03T12:08:31Z 2015-03
dc.description File contents/n-----------------/nProtein_Drug_Interactions.tsv/nInteractions of 96/475 cancer driver genes in Drivers Database with therapeutic agents/nProtein_druggability.tsv/nExclusvie druggability of 157/475 driver genes according interactions in Protein_Drug_Interactions.tsv/nDrug_details.tsv/nDescription of each drug/nDrug_FDAapproved_rules.tsv/nRules for prescription of FDA approved drugs to genomic alterations/nDrug_ClinicalTrials_rules.tsv/nRules for prescription of drugs in clinical trials to genomic alterations/nDrug_resistances_rules.tsv/nRules for not prescribing drugs to samples bearing genomic alterations of primary resistance/n/nSpecificities/n-----------------/n*In most of the files tumor types are represented through its acronyms (see Drivers Database)/n*Specific genomic dependencies/evidences/resistances are codified in the same unified code in the Columns () in the files (Drug_resistances_rules.tsv, Drug_FDAapproved_rules.tsv, Drug_ClinicalTrials_rules.tsv). /nThe coding rules are:/n- All of them are divided in mutations/CNAs/fusions. /n- For each one, different genes with alterations are semicolon (;) divided./n- Each gene differs from its alterions with colon(:) and its different alterations are comma (,) divided. /ni.e BRAF:V600E,V600K (two diferent alterations)/n- For CNAs A stants for Amplification and D for delention./ni.e. FGFR1:A/n- For mutations all of them are specified at protein level lik referenceAA+proteinposition+alteredAA./ni.e. BRAF:V600E,V600K/n except mutational requirements not based on AA change but specific consequence type, which are specified by ::CT:: after the gene./ni.e. NOTCH1::CT::missense_variant:2380-2445;CT::feature_truncation:2380-2445/n- Fusion partners are divided with dash (-)./ni.e. BCR-ABL1/n- A dot (.) represents any./ni.e. BRAF:V600. (any alteredAA)/ni.e. BRAF:. (any PAM mutation)
dc.description.abstract This database contains data on the interactions with therapeutic agents an driver genes contained in Cancer Drivers Database (2014.12). It characterizes the interacting therapeutic agents in terms of clinical phase and cancer prescription, among other features. Additionally, it contains ancillary information on specific genomic alterations associated to drug effectiveness which are FDA approved or clinically being tested together with data on other genomic alterations known to be responsible of drug primary resistance.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher Universitat Pompeu Fabra
dc.relation Més informació: IntOGen (web)
dc.relation Rubio-Perez C, Tamborero D, Schroeder MP, Aantolín AA, Deu-Pons J, Perez-Llamas C, Mestres J, Gonzalez-Perez A, Lopez-Bigas N. In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities. Cancer Cell. 2015; 27(3): 382-96. DOI: 10.1016/j.ccell.2015.02.007
dc.rights Universitat Pomper Fabra License Agreement. Consulteu les condicions d'ús específiques dins del document
dc.title IntOGen - Cancer Drivers Actionability Database
dc.type info:eu-repo/semantics/other
dc.type Dataset
dc.subject.keyword Cancer driver
dc.subject.keyword Biomarkers
dc.subject.keyword Drugs database
dc.rights.accessRights info:eu-repo/semantics/openAccess

This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search


My Account


Compliant to Partaking